The independent source for health policy research, polling, and news.
321 - 340 of 1,288 Results
Lupron, a drug patented half a century ago, treats advanced prostate cancer. Itâs sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals â which may pay nearly as little for the drug â charging so much more to administer it?
With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate â even though itâs a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHNâs Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Recent leaps in medical research have lent urgency to the quest to develop a vaccine against Epstein-Barr, a ubiquitous virus that has been linked to a range of illnesses, from mononucleosis to multiple sclerosis and several cancers.
People now have at their disposal more medicines that are effective at reducing weight, but none can counter obesity alone. One big problem: Insurance coverage remains spotty, and the costly drugs may be needed long term.
An industry has grown up around sleep apnea, stirring concerns about overdiagnosis and overtreatment.
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agencyâs reviews have gone much faster â perhaps too fast.
Congress has once again decided not to decide how to fund the federal government in time for the start of the fiscal year, racing toward a midnight Sept. 30 deadline to pass a stopgap bill that would keep the lights on for two more months. However, it does appear the FDAâs program that gets drugmakers to help fund some of the agencyâs review staff will be renewed in time to stop pink slips from being sent. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Victoria Knight of Axios join KHNâs Julie Rovner to discuss these topics and more. Also this week, Rovner interviews filmmaker Cynthia Lowen, whose new documentary, âBattleground,â explores how anti-abortion forces played the long game to overturn Roe v. Wade.
Massachusetts is the latest state to settle with St. Louis-based Centene Corp. over allegations that it overcharged Medicaid prescription drug programs.
KHN gives readers a chance to comment on a recent batch of stories.
After a unanimous ruling from the high court, doctors who are accused of writing irresponsible prescriptions can go to trial with a new defense: It wasnât on purpose.
The Affordable Care Act required that health insurers provide many medical screenings and prevention services at no out-of-pocket cost to health plan members. But insurers and employers may consider adding cost sharing for preventive services now that a federal court ruled the ACAâs mandate is unconstitutional.
California and New York would be the first states to require anyone under 18 to obtain prescriptions to purchase over-the-counter weight loss products, which some research has linked to eating disorders.
In this episode, Julie Rovner, chief Washington correspondent for KHN, guides listeners through decades of dealings between Congress and Big Pharma.
With fears of a winter surge looming, government agencies have authorized and encouraged vaccination with a newly formulated booster. But the science to support that decision remains inconclusive.
KHN gives readers a chance to comment on a recent batch of stories.
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHNâs Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Inflation hasnât hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasnât materialized.
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldnât result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
Republicans say Democrats are wrong to claim that birth control could be the Supreme Courtâs next target. But Democrats have plenty of evidence that it might be.
© 2026 Âé¶čĆźÓĆ